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Abstract: Human skin-derived precursors (SKP) represent a group of somatic stem/precursor cells
that reside in dermal skin throughout life that harbor clinical potential. SKP have a high self-renewal
capacity, the ability to differentiate into multiple cell types and low immunogenicity, rendering them
key candidates for allogeneic cell-based, off-the-shelf therapy. However, potential clinical application
of allogeneic SKP requires that these cells retain their therapeutic properties under all circumstances
and, in particular, in the presence of an inflammation state. Therefore, in this study, we investigated
the impact of pro-inflammatory stimulation on the secretome and immunosuppressive properties
of SKP. We demonstrated that pro-inflammatory stimulation of SKP significantly changes their
expression and the secretion profile of chemo/cytokines and growth factors. Most importantly,
we observed that pro-inflammatory stimulated SKP were still able to suppress the graft-versus-host
response when cotransplanted with human PBMC in severe-combined immune deficient (SCID) mice,
albeit to a much lesser extent than unstimulated SKP. Altogether, this study demonstrates that an
inflammatory microenvironment has a significant impact on the immunological properties of SKP.
These alterations need to be taken into account when developing allogeneic SKP-based therapies.
Keywords: immunogenicity; inflammation; adult stem cells; skin stem cells; stem
cell-microenvironment interactions; cytokines
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1. Introduction
Human skin is an easily accessible and readily available tissue that contains a broad stem cell
repertoire, including hematopoietic and endothelial precursors, resident epidermal and mesenchymal
stromal cells (MSC), melanocytic stem cells and so-called human skin-derived precursor cells (SKP) [1].
SKP represent a group of dermal stem/precursor cells that are obtained from primary dermal spheroids,
cultivated under low attachment conditions in basic fibroblast growth factor (FGF) and epidermal
growth factor (EGF) rich neurosphere medium [2]. SKP persist throughout adulthood in the human
dermis [2,3] and can be isolated and expanded in large quantities from small skin biopsies of
abdomen [3], breast [3], arm [4], foreskin [5], face [1] and scalp [1,6] tissue.
Historically, SKP were thought to represent a single multipotent dermal precursor cell type with
multilineage differentiation capacity [2,7–10], but research by Izeta and colleagues has shown that
SKP actually represent a heterogeneous group of dermal precursor cells [11]. SKP are of particular
interest for regenerative medicine as they share several properties with embryonic neural crest-derived
stem cells, a group of highly plastic cells with unique properties that reside within the developing
embryo [2,12,13]. In particular, we and others have shown that SKP are able to generate (1) neuronal
cells such as Schwann cells [7,14,15], catecholaminergic [16], dopaminergic [17] and enteric [18]
neurons, (2) mesodermal cell types including adipocytes, chondrocytes, osteocytes [2] and vascular
smooth muscle cells [19] and (3) endodermal progeny such as hepatic cells [5,9,20,21] and islet-like
insulin-producing cells [22].
In the context of cell therapeutic applications of SKP, we previously reported that SKP are poorly
immunogenic and are able to modulate the allogeneic immune response both in vitro and in vivo [23].
These cells therefore not only represent promising candidates for future autologous therapy, but also
for allogeneic cell-based off-the-shelf applications. Their translational potential is being investigated
in preclinical animal models of spinal cord injury [7,24], bone repair [8] and wound healing [25–28].
In many of these degenerative diseases, however, a pronounced inflammatory microenvironment
is present [29–31] that might increase the immunogenicity of SKP, facilitate their rejection and thus
hamper their future therapeutic application.
In this study, we investigated the impact of pro-inflammatory stimulation on the biological
properties, secretome, immunogenicity and immunosuppressive capacity of SKP. Briefly, we first defined
the impact of an inflammatory environment on the cell viability, size and granularity of SKP, because it
has been shown for other postnatal stem cells, e.g., MSCs, that the loss of typical fibroblast-like spindle
shape and differences in granularity, can lead to elevated morphological abnormality, inhomogeneity
and reduced differentiation capacity [32]. In the context of cellular immunogenicity, we investigated
whether inflammation induces changes in the secretion of growth factors, chemokines and cytokines by
SKP and whether SKP become more immunogenic. Most importantly, we examined if pro-inflammatory
stimulated SKP maintain their immunosuppressive capacity in vitro and in vivo.
2. Materials and Methods
2.1. Isolation and Cultivation of Human SKP
SKP were isolated and subcultivated as previously described [5]. As all foreskin samples
were derived from young children, informed consent was obtained from their legal guardians.
All experiments were approved by the Ethical Commission of the UZ Brussels and were performed
in accordance with their guidelines and regulations. The median age of the donors was 3 years
(male, range 1–12 years old) and samples from a total of 9 donors were used throughout the
experiments. Approximately two weeks after isolation, SKP spheroids are broken down to single
cells using 0.2 mg/mL Liberase DH (Sigma-Aldrich, Overijse, Belgium) for 12 min at 37 ◦C. They are
subsequently cultivated for 24 h in SKP growth medium supplemented with 5% (v/v) fetal bovine
serum (FBS; Hyclone, Perbio, Aalst, Belgium) to promote adherence of the cells to the plastic. The next
day, the attached SKP are washed and further cultivated in SKP growth medium without FBS until
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further use. A cell density of 2 × 104 cells/cm2 is applied. SKP between passages 2 and 4 are used for
further experiments.
2.2. Pro-Inflammatory Stimulation
The impact of an inflammatory environment on SKP is evaluated as previously described [33].
Briefly, SKP are stimulated for 18 h using a cocktail of pro-inflammatory cytokines: 25 ng/mL interleukin
(IL)-1β (Peprotech, Rocky Hill, USA), 1 × 103 U/mL interferon (IFN)-γ, 50 ng/mL tumor necrosis factor
alpha (TNFα), and 3 × 103 U/mL IFN-α (all from Prospec Inc, Rehovot, Israel).
2.3. Acquisition and Activation of Immune Cells for In Vitro Assays
Human peripheral blood (PB) samples were collected from healthy donors after informed consent
was obtained. All blood collections were approved by the Ethical Commission of the Jules Bordet
Institute and performed in accordance with their guidelines and regulations. Peripheral blood
mononuclear cells (PBMC) are isolated by Ficoll-Hypaque (Sigma-Aldrich, Overijse, Belgium)
gradient centrifugation of PB. Total CD3+ T-lymphocytes are purified by positive selection using
magnetic-activated cell sorting (MACS) technology (Miltenyi Biotec GmbH, Leiden, The Netherlands)
according to the manufacturer’s instructions. The purity of the selected cells is always above 95%
as determined by flow cytometry. Subsequently, purified CD3+ T-cells are activated (ST; stimulated
T-cells) or not (NST; not stimulated T-cells) with 5 µg/mL of phytohemagglutinin (PHA; Remel,
Thermo-Scientific, Merelbeke, Belgium) and 20 U/mL of IL-2 (Biotest AG, Germany).
2.4. Morphology
Morphological changes are assessed by phase contrast microscopy (100×) using an inverted
microscope (Leica, Machelen, Belgium).
2.5. Viability Assay
SKP viability is determined by using the BD Via-ProbeTM viability staining solution
(7-amino-actinomycin D; 7-AAD). Briefly, SKP are harvested using Tryple Select (Thermo Scientific,
Merelbeke, Belgium) and stained with 0.25 µg of the nucleic acid dye 7-AAD during 10 min at
room temperature. Stained SKP are immediately analyzed with the MACSQuant flow cytometer
(Miltenyi Biotec GmbH, Leiden, The Netherlands).
2.6. Cell Size and Granularity
The cell size (µm) of SKP is defined by flow cytometry-based comparison to standard microbeads
(Miltenyi Biotec GmbH, Leiden, The Netherlands) whereas their granularity is determined by evaluating
the median fluorescence intensity (MFI) of side scatter (SSC).
2.7. Microarray Data Analysis
Total RNA is extracted using the TriPure Isolation ReagentTM (Roche Applied Science, Overijse,
Belgium) and quantified at 260 nm using a NanodropTM spectrophotometer (Thermo Scientific,
Merelbeke, Belgium). The microarrays are performed as previously described using Affymetrix
Human Genome U133 plus 2.0 arrays (Affymetrix, Thermo Scientific, Merelbeke, Belgium) [10].
Background correction, summarization (median polish) and normalization (quantile) are done with
Robust Multiarray Analysis [34]. The data discussed in this publication have been deposited in the
NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE48757.
Heatmaps and volcano plots are generated using the Transcriptome Analysis Console (TAC) version
4.0 (Applied Biosystems, Thermo Scientific, Merelbeke, Belgium).
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2.8. Immunogenicity Assay
Prior to the assay, 1 × 105 allogeneic SKP are plated for pre-adherence and treated (SKP+INFL) or
not (SKP) with the inflammatory cytokine cocktail for 18 h, as described above. T-cells are activated
with 5 µg/mL of PHA (Remel, Thermo Scientific, Merelbeke, Belgium) and 20 U/mL of IL-2 (Biotest AG,
Dreieich, Germany) as described above, and then added to SKP cultures for 5 days of coculture.
T-cell proliferation is assessed by carboxyfluorescein diacetate N-succinimidyl ester (CFDA-SE)
labeling using the CellTraceTM CFSE Cell proliferation kit (Thermo Scientific, Merelbeke, Belgium)
following the protocol described by the manufacturer. Briefly, 2.5 × 105 CD3+ T-lymphocytes are
stained with 10 µM of CFDA-SE prior to coculture with SKP(+INFL). After the coculture period,
CFSE-based fluorescence is analyzed by flow cytometry.
2.9. Secretion Assay
Human cytokine (ab133998) and growth factor (ab134002) antibody arrays (both from Abcam,
Cambridge, UK) are used to detect major changes in the secretion profile of SKP upon proinflammatory
stimulation. Briefly, 1 × 106 SKP are stimulated or not with the pro-inflammatory cocktail, as described
above, and culture medium is collected after 72 h. The antibody array assay is performed according
to the manufacturer’s instructions and chemiluminescent detection is done on a ChemiDocTM MP
Imaging System (Bio-rad, Temse, Belgium). Densitometry is performed to evaluate relative changes
in the secretion profile of SKP stimulated or not with the pro-inflammatory cocktail using Bio-rad’s
Image Lab v.5.2.1 software.
Relative secretion levels are calculated as follows: summed signal intensities for each marker of
interest are used. Background correction is done by subtracting the average summed signal intensities
of the negative control spots. Data normalization across arrays is accomplished by defining one array
as a “reference” to which the other arrays are normalized using the average summed signal intensities
of the positive control spots. Next, for each marker of interest, the average summed signal intensities
of the respective medium controls, either with or without pro-inflammatory cocktail, are subtracted
from the samples. Finally, the obtained secretion levels for SKP with pro-inflammatory stimulation are
calculated as fold change versus control SKP.
2.10. Cotransplantation of PBMC and SKP in SCID Mice
The local Ethical Committee for Laboratory Animal Experiments of the University of Ghent
approved all described mice experiments. Briefly, human PBMC are isolated from a buffy coat
(Blood Transfusion Centre - Ghent) by isopycnic density gradient centrifugation. Hu-PBL-SCID mice
are produced essentially as described before [35]. Briefly, one day before transplantation, SCID mice
(Prkdcscid/Prkdcscid) receive total body irradiation (300 rad) and are injected intraperitoneally with
1 mg of TM-β1, a rat monoclonal antibody that targets the β-chain of the murine IL-2 receptor.
It was previously shown that TM-β1 pretreatment efficiently depletes mouse NK cells in vivo [36].
In the spleen of the SCID mice, either 5 × 106 PBMC, 1 × 106 SKP, 1 × 106 SKP+INFL or a mixture of
5 × 106 PBMC and 1× 106 SKP or SKP + INFL (5:1 cell ratio) is injected. One, two, three and four weeks
after transplantation, mice are weighed and mouse EDTA plasma is collected. The concentration of
human IgG is measured with a human IgG ELISA Quantitation Set (Bethyl Laboratories, Montgomery,
AL, USA) according to the protocol provided by the manufacturer.
2.11. Statistical Analysis
The results are expressed as the mean± standard error of the mean (SEM). For statistical comparison
of more than two groups in the immunogenicity assay, a one-way ANOVA with Bonferroni’s correction
is performed. For statistical comparison of the untreated versus the pro-inflammatory condition, the
unpaired nonparametric two-tailed Mann-Whitney U test is performed. A p-value less than 0.05 is
considered statistically significant (Prism v5.0d, Graph-Pad Software, La Jolla, CA, USA).
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3. Results
3.1. Inflammation Alters the Cytokine and Growth Factor Secretion Profile of SKP
To assess the impact of an inflammatory environment, SKP are stimulated with a cocktail of
pro-inflammatory cytokines (SKP + INFL) for 18h. Upon pro-inflammatory stimulation, SKP preserve
their fibroblast-like morphology and mean cell size (Figure 1a–c). However, a significant decrease in
cell viability (approximately 15%) could be observed for SKP + INFL (83.28 ± 0.66%) compared to SKP
(98.56 ± 0.17%) (Figure 1d). A significant increase in cellular granularity and more variation in cell size
was also observed, indicating increased population heterogeneity (Figure 1c,e).
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Figure 1. Impact of inflammation on biological properties of SKP. SKP preserve (a,b) their fibroblast-like
morphology, but show (c) increased variation in cell size upon pro-inflammatory stimulation.
The (d) viability and (e) granularity of SKP are determined under normal and inflammatory
conditions. The values are expressed as mean ± SEM of four different SKP donors. * Significantly
decreased versus SKP (p-value < 0.0001); ** Significantly increased versus SKP (p-value < 0.0001).
Whole transcriptome and secretome a l s reveal that pro-inflammatory stimulation
significantly a ters the expression of chemoki tokines and growth factors in SKP (Figure 2a–g;
Table 1). More specifi ally, gen xpres ion i r rr y analyse show that the mRNA levels of the
chemokine ligands CCL2 (4.7-fold), CCL5 (676.8-fold), CCL7 (37.6-fold), CCL8 (289.3-fold), CXCL9
(459.5-fold), CXCL10 (1135.8-fold) and CXCL11 (1335.4-fold) as well as of the cytokines interleukin
15 (IL15; 3.7-fold), IL23A (15.4-fold), IL32 (10.9-fold) and IL33 (51.6-fold) are significantly increased
in SKP upon pro-inflammatory stimulation (FDR p-value < 0.05; Figure 2a,b,e,f). Messenger RNA
levels of the trophic factors hepatocyte growth factor (HGF) (32.9-fold), transforming growth factor B1
(TGFB1) (2.8-fold) and vascular endothelial growth factor B (VEGFB) (-3.0-fold) are also found to be
significantly modulated (FDR p-value < 0.05; Figur 2c,d).
Furthe m re, secr tome antibody array analyses show that inflammation significantly increases the
secretion of the chemokine ligands CCL2 (3.1-fold; MCP-1), CCL5 (34.2-fold; RANTES), CCL7 (159.6-fold;
MCP-3), CCL8 (85.2-fold; MCP-2), CCL20 (147.5-fold; MIP-3a), CXCL1 (2.3-fold; GRO), CXCL5 (15.2-fold;
ENA-78), CXCL6 (9.8-fold; GCP2) and CXCL10 (13.2-fold; IP-10). Constitutively, SKP secrete the chemokine
ligands CCL2 (MCP-1), CCL5 (RANTES, CXCL1 (GRO) and CXCL10 (IP-10) as well as HGF, insulin
growth factor binding protein (IGFBP) 2 and 6, IL8, leukemia inhibitory factor (LIF), tissue inhibitor of
metalloproteinases (TIMP) 1 and 2, and VEGF (Table 1; Figure 2g; Supplementary Figure S1).
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Figure 2. Inflammation alters the secretome of SKP and leads to drastically increased HGF secretion
levels. Volcano plots and heatmaps representing (a,b) chemokine, (c,d) growth factor and (e,f) cytokine
mRNA expression changes in SKP + INFL versus SKP. (g) Superimposed graph showing the protein
secretion levels in SKP (blue bar) and SKP + INFL (blue + red bar). The values are expressed as mean ±
SEM and originate from at least 3 different SKP donors. ** Significantly increased secretion versus SKP
(p-value < 0.05).
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The secretion of the colony stimulating factors (CSF) 2 (22.9-fold; GM-CSF) and CSF3 (54.7-fold;
GCSF), HGF (29.3-fold), IGFBP2 (3.5-fold), IL6 (11.1-fold) and 8 (2.3-fold), LIF (6.2-fold), TIMP2 (4.3-fold),
tumor necrosis factor receptor superfamily (TNFRSF; 8.4-fold) 11B (also known as osteoprotegerin)
and VEGF (2.7-fold) are also significantly up-regulated in SKP upon pro-inflammatory stimulation
(Table 1; Figure 2a–g; Supplementary Figure S1). Moreover, in-depth upstream regulator analyses
using Ingenuity Pathway Analysis software predict CCL2 (activation z-score = 2.190), CSF2 (activation
z-score = 2.285), IL6 (activation z-score = 5.173) and LIF (activation z-score = 2.492) to be activated
regulators in SKP upon pro-inflammatory stimulation. Furthermore, the strong increase in HGF
secretion by SKP in the presence of inflammation is evidently a direct consequence of their combined
activation, as shown by pathway mapping of the respective active upstream regulators (Figure 3).
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Figure 3. Upstream regulator interaction mapping. Mechanistic network f t e strea regulators
CCL2, CSF2, IL6 and LIF (green circle) that are predicted to be activated in SKP in a pro-inflammatory
environment. Their combined activation is predicted to significantly contribute to the strong increase in
HGF (blue circle) secretion by SKP in the presence of inflammation. Legend: red represents increased
and green decreased gene expression upon pro-inflammatory stimulation. Figure produced using
Ingenuity Pathway Analysis Software.
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Table 1. Secretome of SKP is Altered by Inflammation.
Gene Expression Protein Secretion
Gene Probeset Fold Change FDRp-Value Protein SKP SKP+INFL Fold Change p-Value
CCL2
(*) 216598_s_at 4.7 2.81 × 10
−2 MCP-1
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Cells 2020, 9, x FOR PEER REVIEW 9 of 16 
 
6 206336_at 3.2 .82 × 10−1 GCP-2 
  
9.8 1.00 × 10−4 
CXCL10 204533_at 1135.8 5.50 × 10−3 IP-10 
  
13.2 6.00 × 10−4 
CSF2 
(*) 
210229_s_at 39.1 3.98 × 10−1 GM-CSF 
  
22.9 8.80 × 10−3 
CSF3 207442_at 38.0 1.00 × 10−1 GCSF 
  
54.7 3.40 × 10−3 
HGF 210997_at 32.9 1.28 × 10−2 HGF 
  
29.3 3.00 × 10−4 
IGFBP2 202718_at 5.2 1.04 × 10−1 IGFBP2 
  
3.5 3.59 × 10−2 
IGFBP6 203851_at 1.0 5.27 × 10−1 IGFBP6 
  
1.4 2.27 × 10−2 
IL6 
(*) 205207_at 4.9 1.87 × 10
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Table 1. Cont.
Gene Expression Protein Secretion
Gene Probeset Fold Change FDRp-Value Protein SKP SKP+INFL Fold Change p-Value
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3.2. SKP Remain Immunosuppressive Upon In Vitro Pro-inflammatory Stimulation
We observed that SKP maintain their ability to suppress T-cell proliferation in vitro after
pro-inflammatory stimulation, as indicated by the absence of expanded T-cell colonies in
coculture conditions (Figure 4a,b). Moreover, a significant (approximately 50%) inhibition of
T-cell proliferation was achieved in both the control and inflammatory condition (Figure 4a,b).
Pro-inflammatory-stimulated SKP do not initiate an allogeneic lymphocyte proliferative response, as
no significant proliferation of not-stimulated CD3+ T-cells (NST) was observed in the presence of SKP
+ INFL (Figure 4a,b).
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Furthermore, NST constitutively express the immune regulatory proteins CD25 (46.22 ± 3.55%),
CD38 (62.68 ± 1.84%), CD69 (30.19 ± 0.89%), OX40 (66.44 ± 1.73%; also known as CD134 and
TNFRSF4), CD154 (81.88 ± 3.24%; also known as CD40L) and HLA-DR (98.78 ± 0.32%) (Figure 4c–h).
Upon coculture of NST with SKP, without (72.32 ± 2.88%) and with (78.03 ± 2.06%) inflammatory
stimulation, the expression of CD69 is significantly increased (Figure 4e). However, no significant
changes are found in the expression of CD25, CD38, OX40, CD154 and HLA-DR by NST (Figure 4c–h).
3.3. Inflammation Alters the Immunosuppressive Properties of SKP In Vivo
To compare the in vivo immunosuppressive capacity of SKP, in the presence or absence of
inflammation, we transplanted control or pro-inflammatory stimulated SKP alone, or together with
human peripheral blood mononuclear cells (PBMC) in severe combined immune deficient (SCID) mice
and investigated the graft-versus-host response. We observed that transplantation of both control
and pro-inflammatory stimulated SKP does not have any detrimental effects on the health of the
SCID mice as indicated by the normal body weight of the mice (Figure 5a). This is opposed to the
transplantation of human PBMC that induce a severe graft-versus-host response and exhibit a strong
negative effect on the health of the mice, as shown by the gradual loss in bodyweight and low survival
rate (Figure 5b). Cotransplantation of human PBMC with control or pro-inflammatory stimulated SKP
preserves the overall health status of the mice and prevents death (Figure 5a,b). Indeed, no significant
differences were observed in survival time and body weight of PBMC cotransplanted mice between
SKP and SKP+INFL (Figure 5a,b). However, significantly higher levels of human IgG in the blood
of the mice were found on day 28 post transplantation for the PBMC/SKP+INFL (1.41 ± 0.37 ng/mL)
condition compared to PBMC/SKP (0.40 ± 0.26 ng/mL), pointing to an important impairment of the
immunosuppressive capacity of SKP when stimulated by pro-inflammatory factors (Figure 5c).
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Figure 5. Pro-inflammatory stimulation of SKP alters, to some extent, their immune
suppressive properties. (a,b) Unstimulated and pro-inflammatory stimulated SKP both
suppress the graft-versus-host response of cotransplanted human PBMC in SCID mice.
However, (c) cotransplantation of PBMC with pro-inflammatory stimulated SKP results in significantly
higher human IgG blood levels compared to cotransplantation with unstimulated SKP, suggesting
a lower in vivo immune suppressive capacity of SKP+INFL. * Significantly increased versus PBMC
(p-value < 0.05); ** Significantly increased versus PBMC+SKP (p-value < 0.05).
4. Discussion
Human skin-derived precursors are a promising postnatal stem cell population for cellular therapy,
as they exhibit multilineage differentiation capacity [5,7,8,16,19,22]. Furthermore, we previously
showed that SKP are poorly immunogenic and exhibit favorable immunosuppressive properties [23].
As such, SKP are considered immunologically privileged, as they do not express the complete
set of molecules required to fully activate T-cells, and do not stimulate their proliferation [23].
Moreover, they are able to suppress the allogeneic activation of T-cells due to a combination of
direct cell contact and the secretion of soluble immune inhibitory factors, thereby inhibiting the
graft-versus-host response both in vitro and in vivo [23]. It is believed that due to these features,
SKP may constitute a valuable and easily accessible cell source for off-the-shelf-based cellular
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therapy [23]. However, one of the major safety concerns associated with stem cell-based therapies
is the risk of host rejection related to unforeseen changes in the immunogenicity of the transplanted
donor cells [37]. As such, patients would require life-long immune suppressant therapy. In this context,
the cellular microenvironment and inflammatory milieu play key roles in determining the phenotype
and the effects of immunomodulatory cells, including MSCs, on the immune system [38–40]. In many
degenerative diseases for which cellular therapy could be considered, a pronounced inflammatory
environment is often present [29–31]. This might increase the immunogenicity of SKP and facilitate their
rejection, thus limiting their therapeutic application. Hence, potential clinical application of allogeneic
SKP requires that these cells remain poorly to nonimmunogenic under all circumstances, including in
a pro-inflammatory environment. In this study, we therefore investigated the impact of inflammation
on the immunogenicity and immunosuppressive properties of SKP. We found that inflammation
decreases the cell viability of SKP only to a limited extent. However, it also introduced a degree
of heterogeneity within the cell population, as evidenced by variations in cell size and granularity.
This could prelude the hampered functioning of a subset of cells within the SKP population [32].
Consequently, in cell therapy settings using SKP, a surplus of at least 15% of cells should be considered
to compensate for the cell loss and population heterogeneity due to the presence of inflammation.
It might therefore be important to monitor the inflammatory status of patients at the time therapeutic
cells are infused to optimize cell-based therapies [41].
In our study, we found that pro-inflammatory-stimulated SKP maintain their immunosuppressive
properties and induce the expression of CD69 in T-cells, but do not initiate an allogeneic lymphocyte
proliferative response, as is also observed for unstimulated SKP. CD69 is a critical receptor for
controlling regulatory T-cell (Treg)-suppressor function and acts as a regulatory molecule by modulating
transforming growth factor (TGF) β levels at the site of inflammation [42,43]. Furthermore, we found
that SKP increase their secretion of chemokines and cytokines involved in leukocyte chemotaxis
upon pro-inflammatory stimulation, including the secretion of CCL2 (MCP-1), CCL5 (RANTES),
CCL7 (MCP-3), CCL8 (MCP-2), CCL20 (MIP-3a), CXCL1 (GRO), CXCL5 (ENA-78), CXCL6 (GCP-2),
CXCL10 (IP-10), IL6 and IL8 [44,45]. These chemotaxis proteins might attract immune cells to the site
of transplantation and hamper their engraftment or therapeutic functioning. In addition, SKP+INFL
also significantly increase their secretion of CSF2 (GM-CSF) and CSF3 (GCSF), two cytokines involved
in hematopoiesis where they control the production, differentiation and function of granulocytes and
macrophages [46]. An intriguing finding was the increased protein secretion of TIMP2 and OGN
(TNFRSF11B) while their gene expression was decreased. This discrepancy might be explained by
the fact that we quantified the extracellular secretion of proteins and not total protein production.
Protein production might be—but is not necessarily—decreased when gene expression is lower,
while protein secretion is increased upon exogenous stimulation. Importantly, a highly increased
secretion of HGF is observed in SKP upon pro-inflammatory induction. HGF is known to be
a potent immunomodulatory factor that inhibits dendritic cell function along with differentiation of
IL-10-producing T-cells, promotion of regulatory T-cell generation, a decrease in IL-17-producing T-cells
and down-regulation of surface markers of T-cell activation [47–49]. Previously, we showed that HGF
secretion is mandatory for the immunosuppressive functions of SKP towards CD3+ T-cells, and that by
addition of HGF-neutralizing antibodies, a significantly lower T-cell inhibition could be observed [23].
It can be speculated that the increase in HGF secretion upon pro-inflammatory stimulation preserves
the immunosuppressive capacity of SKP towards CD3+ T-cells. Using in-depth pathway analyses,
we could show that this observation is linked to the combined activation of CCL2, CSF2, IL6 and
LIF. For the first time, these results provide information on the secretome of SKP, and thus, also on
their paracrine signaling under normal and pro-inflammatory conditions. In addition, we found
that cotransplantation of pro-inflammatory stimulated SKP with human PBMC in SCID mice also
suppressed the graft-versus-host response, albeit to a lesser extent than unstimulated SKP. Injection of
PBMC allowed us to investigate the impact on B-cell activation and the production of human IgG as a
graft-versus-host response. Indeed, although no significant differences were observed in the survival
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time and body weight of cotransplanted mice between human SKP and SKP+INFL, significant higher
levels of human IgG in the blood of the mice were found for PBMC+SKP+INFL compared to PBMC+SKP.
These data indicate that the stimulation of SKP with pro-inflammatory cytokines, present in the
inflammatory environment of degenerative diseases, hampers their immunosuppressive capacity.
Altogether, our study demonstrates that the local microenvironment greatly influences the
properties and functionality of SKP, and that these changes need to be well-understood and considered
when developing future SKP-based therapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/4/914/s1, Table S1:
Antibodies used for flow cytometry; Figure S1: Secretome analyses of SKP upon pro-inflammatory stimulation.
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